China Aoxing Pharmaceutical Corp. Announces Submission of NDA of Its Leading Narcotic Drug for the Treatment of Acute Moderate to Severe Cough

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that Ceplene® (histamine dihydrochloride) has been highlighted in two separate reports issued recently reviewing 2008 drug approvals in the European Union. One report, issued by the U.K. publication Mednous, said that Ceplene® was one of 12 products “expected to confer major public health benefits,” while the European Medicines Agency (EMEA), in its summary of the annual report for 2008, stated, “Of the 66 medicines to receive a positive opinion from the CHMP in 2008, those that are of particular note include: the first medicine for use as a maintenance treatment in adults with acute myeloid leukemia…”

Back to news